

<b>Application Number</b>	10/799,977- GAU 3774
<b>Filing Date</b>	March 12, 2004
<b>First Named Inventor</b>	Miller, Richard L.
<b>Art Unit</b>	3736
<b>Examiner Name</b>	Unknown
<b>Attorney Case Number</b>	58515US004

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Page 1 of 4

## **U.S. Patent Documents**

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number (Kind Code if Known)			
	A1	US- 3,314,941	04-18-1967	Littell et al.	
	A2	US- 4,689,338	08-25-1987	John F. Gerster	
	A3	US- 4,698,348	10-06-1987	John F. Gerster	
	A4	US- 4,929,624	05-29-1990	Gerster et al.	
	A5	US- 4,988,815	01-29-1991	Andre et al.	
	A6	US- 5,037,986	08-06-1991	John F. Gerster	
	A7	US- 5,175,296	12-29-1992	Gerster	
	A8	US- 5,238,944	08-24-1993	Wick et al.	
	A9	US- 5,266,575	11-30-1993	John F. Gerster	
	A10	US- 5,268,376	12-07-1993	John F. Gerster	
	A11	US- 5,346,905	09-13-1994	John F. Gerster	
	A12	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A13	US- 5,367,076	11-22-1994	Gerster	
	A14	US- 5,389,640	02-14-1995	Gerster et al.	
	A15	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A16	US- 5,446,153	08-29-1995	Lindstrom et al.	
	A17	US- 5,482,936	01-09-1996	Kyle J. Lindstrom	
	A18	US- 5,693,811	12-02-1997	Lindstrom	
	A19	US- 5,741,908	04-21-1998	Gerster et al.	
	A20	US- 5,756,747	05-26-1998	Gerster et al.	
	A21	US- 5,939,090	08-17-1999	Beaurline et al.	
	A22	US- 6,039,969	03-21-2000	Tornai et al.	
	A23	US- 6,069,149	05-30-2000	Nanba et al.	
	A24	US- 6,083,505	07-04-2000	Miller et al.	
	A25	US- 6,110,929	08-29-2000	Gerster et al.	
	A26	US- 6,194,425	02-27-2001	Gerster et al.	
	A27	US- 6,245,776	06-12-2002	Skwierczynski et al.	
	A28	US- 6,331,539	12-18-2001	Crooks et al.	

\*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 2 of 4

<b>Application Number</b>	10/799,979-99997 - GAU 3774
<b>Filing Date</b>	March 12, 2004
<b>First Named Inventor</b>	Miller, Richard L.
<b>Art Unit</b>	3736
<b>Examiner Name</b>	Unknown
<b>Attorney Case Number</b>	58515US004

## U.S. Patent Documents

Exam. Init.	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A29	US- 6,376,669	04-23-2002	Rice et al.	
	A30	US- 2002/0055517 A1	05-09-2002	Smith	
	A31	US- 2002/0058674 A1	05-16-2002	Hedenstrom et al.	
	A32	US- 6,451,810	09-17-2002	Coleman et al.	
	A33	US- 6,518,265	02-11-2003	Kato et al.	
	A34	US- 6,525,064	02-25-2003	Dellaria et al.	
	A35	US- 6,541,485	04-01-2003	Crooks et al.	
	A36	US- 6,545,016	04-08-2003	Dellaria et al.	
	A37	US- 6,545,017	04-08-2003	Dellaria et al.	
	A38	US- 6,558,951	05-06-2003	Tomai et al.	
	A39	US- 6,573,273	06-03-2003	Crooks et al.	
	A40	US- 6,656,938	12-02-2003	Crooks et al.	
	A41	US- 6,660,735	12-09-2003	Crooks et al.	
	A42	US- 6,660,747	12-09-2003	Crooks et al.	
	A43	US- 6,664,260	12-16-2003	Charles et al.	
	A44	US- 6,664,264	12-16-2003	Dellaria et al.	
	A45	US- 6,664,265	12-16-2003	Crooks et al.	
	A46	US- 6,667,312	12-23-2003	Bonk et al.	
	A47	US- 6,670,372	12-30-2003	Charles et al.	
	A48	US- 6,677,347	01-13-2004	Crooks et al.	
	A49	US- 6,677,348	01-13-2004	Heppner et al.	
	A50	US- 6,677,349	01-13-2004	Griesgraber	
	A51	US- 6,683,088	01-27-2004	Crooks et al.	
	A52	US- 2002/0016332 A1	02-07-2002	Slade	
	A53	US- 2002/0110840 A1	08-15-2002	Tomai et al.	
	A54	US- 2003/0130299 A1	07-10-2003	Crooks et al.	
	A55	US- 2003/0133913 A1	07-17-2003	Tomai et al.	
	A56	US- 2003/0139364 A1	07-24-2003	Krieg et al.	

\*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /WM/

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 3 of 4

Application Number	10/799,979- GAU 3774
Filing Date	March 12, 2004
First Named Inventor	Miller, Richard L.
Art Unit	3736
Examiner Name	Unknown
Attorney Case Number	58515US004

## U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A57	US- 2003/0161797 A1	08-28-2003	Miller et al.	
	A58	US- 2003/0199538 A1	10-23-2003	Skwirczynski et al.	
	A59	US- 2003/0232852 A1	12-18-2003	Lindstrom et al.	
	A60	US- 2004/0010007	01-15-2004	Dellaria et al.	
	A61	US- 2004/0014779	01-22-2004	Gorden et al.	

## Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (if known)				
	B1	PCT	WO 02/36592	05-10-2002			X
	B2	PCT	WO 03/103584	12-18-2003			
	B3	JP	9-208584	08-12-1997			
	B4	JP	9-255926	03-26-1999			X
	B5	JP	11-222432	08-17-1999			X
	B6	JP	2000-247884 (abs)	09-12-2000			X
	B7	EP	0 394 026	10-24-1990			
	B8	EP	1 104 764	06-06-2001			

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	Wozniak, et al, "The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate <sup>1,2</sup> . A New and Convenient Amination Method.", <u>Journal of the Royal Netherlands Chemical Society</u> , 102, pp 511-513, December 12, 1983.
	C2	Brennan, et al, "Automated Bioassay of Interferons in Micro-test Plates", <u>Biotechniques</u> , June/July, 78, 1983.
	C3	Testerman, et al, "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", <u>Journal of Leukocyte Biology</u> , Volume 58, pp. 365-372, September 1995.
	C4	Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline", <u>J. Org. Chem.</u> , 15, pp 1278-1284 (1950).
	C5	Jain, et al, "Chemical and Pharmacological Investigations of Some $\omega$ -Substituted Alkylamino-3-aminopyridines", <u>J. Med. Chem.</u> , 11, pp 87-92 (1968).
	C6	Baranov, et al., <u>Chem. Abs.</u> 85, 94362, (1976).

\*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /WM/

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)  Page 4 of 4	<b>Application Number</b>	107999799997 - GAU
	<b>Filing Date</b>	March 12, 2004
	<b>First Named Inventor</b>	Miller, Richard L.
	<b>Art Unit</b>	3736
	<b>Examiner Name</b>	Unknown
	<b>Attorney Case Number</b>	58515US004

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Exam. Init.	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C7	Berényi, et al, "Ring Transformation of Condensed Dihydro-as-triazines", <u>J. Heterocyclic Chem.</u> , 18, pp 1537-1540 (1981).
	C8	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", <u>Pharmaceutical Development and Technology</u> , 4(1), pp 35-43 (1999)
	C9	Izumi, et al., "1 <i>H</i> -Imidazo[4,5- <i>c</i> ]quinoline Derivatives as Novel Potent TNF- $\alpha$ Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i> ]pyridines", <u>Bioorganic &amp; Medicinal Chemistry</u> , 11, pp 2541-2550 (2003)
	C10	Hornung et al., "Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides", <u>The Journal of Immunology</u> , 2002, 168; pgs. 4531-4537.
	C11	Hemmi et al., "Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent Signaling pathway", <u>Nature Immunology</u> , vol. 3, no. 2; February 2002; pgs. 196-200.
	C12	Medzhitov, "Toll-Like Receptors and Innate Immunity", <u>Nature Reviews Immunology</u> , Vol. 1; November 2001, pgs. 135-145.
	C13	Jurk et al. "Human TLR7 and TLR8 independently confer responsiveness to the antiviral compound R-848", <u>Nature Immunology</u> , June 2002, vol. 3, no. 6; pg. 1.
	C14	Akira et al., "Toll-like receptors: critical proteins linking innate and acquired immunity", <u>Nature Immunology</u> , August 2001, vol. 2, no. 8; pgs. 675-680
	C15	Heil et al.; "Synthetic immunostimulatory compounds activate immune cells via TLR7 and TLR8"; 33th Annual Meeting of the Deutsche Gesellschaft für Immunologie, Marburg 2002 - Abstract C.6

<b>*Examiner:</b> William Matthews/	<b>Date Considered:</b> 05/22/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.	
Information Disclosure Statement — PTO-1449 (Modified)	